The one thing that I wonder might not be the mesoblast trump card in all of this is being able to share all the jcr data in their treatment of patients in Japan over the last 5 odd years . Given their market share in Japan in this space you would have thought it is absolutely compelling .
I know we all talk about the npv of gvhd to the share price but I really think it misses the point . Getting approval outs stem cells as a treatment on the board . And what we know is that this is a platform technology and meso owns all the keys .
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L, page-372
-
- There are more pages in this discussion • 483 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.5¢ |
Change
-0.015(1.49%) |
Mkt cap ! $1.136B | |||
| Open | High | Low | Value | Volume |
| $1.02 | $1.02 | 99.5¢ | $2.005M | 1.991M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 14424 | 99.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 63643 | 1 |
View Market Depth
| Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |